This study further confirmed that a combination of a PD-1 inhibitor with an anti-VEGFR TKI has favorable clinical efficacy and acceptable toxicity in the treatment of unresectable HCC in patients not previously treated with systemic therapy, and penpulimab combined with anlotinib may be an optional regime. This evidence concerns the gene KDR and hepatocellular carcinoma.